MARCY GOLDBERG: Open Payments
NPI 1295848968 · FRENCH CAMP, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,384 in 28 payments from 12 companies in 2025. Trend: 2023 $520 · 2024 $447 · 2025 $1,384
Long term medical supply or device loan: $997Food & beverage: $387
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $1,083 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Janssen Biotech, Inc. | 1 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| ABBVIE INC. | 1 | $27 |
| Celgene Corporation | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Fennec Pharmaceuticals, Inc. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $18 |
Products named: KISQALI, FRUZAQLA, RYBREVANT, SCEMBLIX, OPDIVO, LIBTAYO, EPKINLY, Fabhalta.
Industry payments across CA — which companies pay providers there.
